Interleukin 23 (IL-23) is required for autoimmune inflammation mediated by IL-17-producing helper T cells (T H -17 cells) and has been linked to many human immune disorders. Here we restricted deficiency in the IL-23 receptor to defined cell populations in vivo to investigate the requirement for IL-23 signaling in the development and function of T H -17 cells in autoimmunity, inflammation and infection. In the absence of IL-23, T H -17 development was stalled at the early activation stage. T H -17 cells failed to downregulate IL-2 and also failed to maintain IL-17 production or upregulate expression of the IL-7 receptor a-chain. These defects were associated with less proliferation; consequently, fewer effector T H -17 cells were produced in the lymph nodes and hence available to emigrate to the bloodstream and tissues.
Interleukin 23 (IL-23) is required for autoimmune inflammation mediated by IL-17-producing helper T cells (T H -17 cells)
and has been linked to many human immune disorders. Here we restricted deficiency in the IL-23 receptor to defined cell populations in vivo to investigate the requirement for IL-23 signaling in the development and function of T H -17 cells in autoimmunity, inflammation and infection. In the absence of IL-23, T H -17 development was stalled at the early activation stage. T H -17 cells failed to downregulate IL-2 and also failed to maintain IL-17 production or upregulate expression of the IL-7 receptor a-chain. These defects were associated with less proliferation; consequently, fewer effector T H -17 cells were produced in the lymph nodes and hence available to emigrate to the bloodstream and tissues.
To establish inflammation in many models of autoimmunity, innate immune cells must produce interleukin 23 (IL-23). IL-23 shares its p40 subunit with IL-12 but has a unique p19 subunit 1 , and it has become apparent that many of the reported associations of IL-12 and T helper type 1 (T H 1) cells with autoimmunity can be explained by a requirement for IL-23 (ref. 2) . Some of the proinflammatory functions of IL-23 seem to be related to the IL-17-producing helper T cell (T H -17 cell) subset 3 . T H -17 cells were initially shown to be a chief pathogenic cell type in models of autoimmunity, including experimental autoimmune encephalomyelitis (EAE) 4, 5 and collagen-induced arthritis 5 , and have since been identified in several human inflammatory diseases, including Crohn's disease 6 and psoriasis 7 . Likewise, polymorphisms in the gene encoding the IL-23 receptor (IL-23R), are important susceptibility factors for these disorders 8, 9 .
Despite those associations, the precise function of IL-23 in T H -17 biology has remained elusive. IL-23R is upregulated on T cells after activation in the presence of inflammatory cytokines such as IL-6 (ref. 10 ). In the presence of proinflammatory cytokines, particularly IL-6, transforming growth factor-b (TGF-b) drives the initial T H -17 differentiation [11] [12] [13] , including expression of the T H -17-specific transcription factor RORgt 10 , which leads to the production of IL-17A (called 'IL-17' here) and IL-17F [11] [12] [13] . However, continued stimulation of T H -17 cells with antigen in the presence of TGF-b and IL-6 does not lead to pathogenic activity of those cells 14 . In addition, abundant production of IL-10 is induced by stimulation of T H -17 cells with TGF-b and IL-6, which can lead to inhibition of T H -17-mediated inflammation. In contrast, IL-23 signaling in T H -17 cells can enhance their pathogenic activity 4 and promote the production of proinflammatory factors 4 , including 16) . Such findings suggest that IL-23-dependent signaling in T H -17 cells is important for their full pathogenic activity.
It has been suggested, mainly on the basis of in vitro observations, that IL-23 stimulation results in greater numbers of already differentiated T H -17 cells, maintains IL-17 production by T H -17 cells or promotes the survival of T H -17 cells. For example, the addition of IL-23 during the culture of activated or memory T cells results in more proliferation 1 and a greater frequency of IL-17 + T cells produced 4 ; IL-23 is also required during restimulation of T H -17 cells (cells previously stimulated with TGF-b and IL-6), to maintain IL-17 production by the T H -17 cells 12 . Similarly, it has been suggested that IL-23 may stabilize the phenotype of T H -17 cells through mechanisms dependent on the transcription factor STAT3 (refs. 17,18) . Two other cytokines thought to be involved in T H -17 differentiation, IL-6 and IL-21, also share the STAT3-dependent signaling pathway with IL-23. Finally, IL-23 has been suggested to be a survival factor for T H -17 cells 19 . Although all of those data are consistent with the observation of lower frequencies of IL-17 + T cells in IL-23-deficient mice 4 , the precise requirements for IL-23 in vivo during the initiation and effector phases of the T H -17-mediated inflammatory response have yet to be investigated. One further factor that complicates the interpretation of results obtained with IL-23-deficient mice is that IL-23 may also have important proinflammatory effects on cells of the innate immune system 2, 20 .
In this report we genetically restricted IL-23R deficiency to defined cell populations in vivo to identify the requirement for IL-23 signaling in autoimmunity of the central nervous system (CNS), skin inflammation and parasite infection. We found that the generation of normal T H -17 cell effector responses, but not T H 1 cell effector responses, required IL-23R-dependent signaling. IL-23 alone is not sufficient for T H -17 development. However, in contrast to previously held assumptions that IL-23 merely maintains the effector function of T H -17 cells, we found that IL-23 was necessary for the full differentiation of activated T cells into effector T H -17 cells.
RESULTS

Failed CNS accumulation of Il23ra -/-CD4 + T cells
We used mice deficient in IL-23R 21 (Il23ra -/-mice) to address the function of IL-23 in T H -17-mediated inflammation in vivo. Similar to results obtained before with IL-23-deficient (Il23a -/-) mice 2 , we found that Il23ra -/-mice were resistant to EAE induction (Fig. 1a) , which confirmed the idea that this receptor is required for IL-23 signaling in vivo. However, this resistance made it impossible to investigate the effects of IL-23 on inflammatory cells in the CNS of these mice. To circumvent that problem, we generated mixed-bone marrow chimeric mice in which 50% of the reconstituting bone marrow was derived from Il23ra -/-CD45.1 -donors and 50% was derived from wild-type CD45.1 + congenic donors ( Supplementary Fig. 1 online) . Thus, wildtype and Il23ra -/-cells could be distinguished on the basis of CD45.1 expression. We also generated control chimeras in which 50% of the donor bone marrow was derived from wild-type CD45.1 -donors and 50% was derived from wild-type CD45.1 + donors. At 8 weeks after the transfer of bone marrow into recipient mice, we found no defect in the ability of Il23ra -/-donor cells to repopulate the T cell, B cell, dendritic cell and macrophage compartments (data not shown). We then evaluated the susceptibility of chimeric mice to EAE induction. We found that mixed Il23ra -/--wild-type (50%/50%) bone marrow chimeras were fully susceptible to EAE, with only a slight delay in onset of clinical signs relative to that of wild-type-wild-type (50%/50%) control chimeras (Fig. 1b) . We then characterized the infiltrating mononuclear cells in the CNS at the onset of EAE (day 11 after immunization) in the chimeric mice. The relative proportions of wildtype and Il23ra -/-macrophages, dendritic cells and CD8 + T cells were similar ( Supplementary Fig. 2 online) , which indicated that the recruitment and accumulation of these cells in the CNS was not dependent on Il23ra. However, there was a much lower proportion of Il23ra -/-CD4 + T cells than wild-type CD4 + T cells at day 11 after immunization ( Fig. 1c) . We next evaluated the proportion of wildtype and Il23ra -/-CD4 + cells at other time points. Before clinical onset of EAE (days [8] [9] , a stage at which T cells first enter the CNS to establish inflammation, wild-type and Il23ra -/-CD4 + T cells were present in similar proportions. However, at onset and during active EAE, the proportion of Il23ra -/-CD4 + cells was much lower than that of wild-type CD4 + cells (Fig. 1d) . The absolute numbers of CD4 + cells reflected that ratio and further emphasized the idea that although the ratios of wild-type and Il23ra -/-cells were similar before onset of EAE, at this stage there were also very low numbers of cells infiltrating the CNS relative to the numbers that had accumulated by the onset of clinical symptoms (Fig. 1e) . Hence, it seemed that wild-type CD4 + cells accumulated normally in the CNS but Il23ra -/-cells did not.
CNS Il23ra -/-T cells produce less IL-17
To determine whether there were additional functional defects in the Il23ra -/-cells, we evaluated their ex vivo cytokine responses to stimulation for 24 h with a peptide of myelin oligodendrocyte glycoprotein (amino acids 35-55; MOG(35-55)) in the presence or absence of IL-23. IL-17 production by CNS Il23ra -/-CD4 + T cells was much lower at day 11 after immunization with MOG (35-55) (Fig. 2a) . IFN-g production was not higher when IL-23 signaling was absent (Fig. 2b) , which indicated that the Il23ra -/-cells had not 'converted' to a T H 1 cell phenotype. The addition of IL-23 to the cultures greatly enhanced the production of IL-17 by wild-type cells (Fig. 2c) , and flow cytometry showed a higher mean fluorescence intensity per IL-17 + wild-type CD4 + T cell (Fig. 2d) , which confirmed that IL-23 promotes T H -17 differentiation. Notably, IFN-g production by T H -17 cells was not enhanced by IL-23 ( Fig. 2e) , which again suggested that IL-23 does not enhance T H 1 responses. When we tested the responses of draining lymph nodes, we found that MOG-specific production of IL-17 was also impaired in Il23ra -/-T cells (Fig. 2f) . This suggested that the requirement for IL-23 signaling began during earlier differentiation in the lymph nodes.
Il23ra -/-T cell populations expand but have impaired function
The results thus far suggested that in the absence of IL-23R, either fewer MOG-specific CD4 + T cells were present or MOG-specific CD4 + T cells had an altered phenotype compared with that of wild-type MOG-specific CD4 + T cells. As the effects of IL-23 were already apparent before T cells left the draining lymph nodes to enter target organs, it became necessary to directly identify the responding antigen-specific cells in vivo. Because we were unable to track MOG-reactive endogenous CD4 + T cells, we instead made use of OT-II CD4 + T cell antigen receptor-transgenic mice that also express the allele encoding CD45.1. By generating Il23ra -/-OT-II mice and transferring small numbers of Il23ra -/-CD45.1 + OT-II T cells into wild-type CD45.2 + recipient mice, we could investigate the consequences of IL-23R deficiency restricted to CD4 + T cells during activation in an environment in which all other cells were IL-23 responsive. Using this system, we assessed antigen-specific wild-type and Il23ra -/-OT-II T cell numbers in draining lymph nodes on day 7 after immunization of the recipient mice with ovalbumin peptide (amino acids 323-339; OVA(323-339)) in complete Freund's adjuvant (CFA) and found that the increase in these cell numbers was IL-23 independent (Fig. 3a) . The absolute number of OT-II cells correlated with the percentage of total CD4 + cells (mean, 3.8 Â 10 5 ± 1.7 Â 10 5 for wild-type OT-II cells, compared with 2.7 Â 10 5 ± 7 Â 10 4 for Il23ra -/-OT-II cells on day 7). We consistently noted a slightly lower frequency of Il23ra -/-cells than wild-type cells during the contraction phase, although the difference was not statistically significant (Fig. 3a) .
To determine the functional ability of the Il23ra -/-OT-II T H 17 cells, we tested whether they could mediate an IL-17-dependent delayed-type hypersensitivity (DTH) reaction 22 . Recipients of Il23ra -/-OT-II cells had a much lower DTH swelling response than that of recipients of wild-type OT-II cells (Fig. 3b) . This finding indicated that the effector response in this system was impaired, which correlated with findings obtained with the EAE model. We next investigated IL-17 production by Il23ra -/-OT-II T cells after immunization. Early induction of IL-17 was unaffected by IL-23R deficiency in vivo (Fig. 3c) , consistent with reported in vitro findings that TGF-b and IL-6 alone are sufficient to induce the production of RORgt and IL- 17 (refs. 10-13) . However, we found that Il23ra -/-cells produced less IL-17 than did wild-type cells at later time points; this was most apparent from day 10 (Fig. 3c) . The timing of this lower IL-17 production correlated well with the impaired IL-17 response to MOG ) stimulation noted at day 11 in lymph nodes and CNS in the mixed-bone marrow chimeras (described above).
The differentiation of inducible regulatory T cells and T H -17 cells expressing the transcription factor Foxp3 seems to be reciprocally regulated 11 . Published data further suggest that IL-23 negatively regulates the generation of regulatory T cells from naive T cells activated in the gastrointestinal system 23 . We speculated, therefore, that conversion to a regulatory T cell phenotype might be 'favored' by Il23ra -/-OT-II cells in response to stimulation with OVA(323-339). However, we detected no increase in Foxp3 expression in lymph node Il23ra -/-OT-II cells after immunization with OVA(323-339) in CFA (Fig. 3d) . Likewise, the proportion of Foxp3 + cells was not affected by IL-23R deficiency in either lymph nodes or CNS after EAE induction in mixed-bone marrow chimeras ( Supplementary Fig. 3 online) .
Activation of the transcription factor STAT3 is crucial for T H -17 development 17 Because other T H -17-associated cytokines, including IL-6 and IL-21, also activate STAT3, we evaluated whether IL-23 could induce phosphorylation of STAT3 in developing T H -17 cells in vivo. After transferring OT-II T cells to and immunizing recipient mice, we collected draining lymph node cells and allowed them to 'rest' briefly before stimulating them with cytokines. We found that 20% of wildtype OT-II T cells responded to IL-23 on days 3-5 after immunization by phosphorylating STAT3, but Il-23ra -/-OT-II T cells did not ( Fig. 3e) , and this response correlated with the proportion of cells that also produced IL-17 on day 5 (data not shown). This result suggested that IL-23R may be regulated depending on the activation status of the cell rather than being upregulated on all T cells after activation. In contrast, most wild-type and Il23ra -/-OT-II cells phosphorylated STAT3 in response to IL-6 ( Fig. 3e) , which indicated that there was no inherent change in ability of the Il23ra -/-OT-II cells to activate STAT3 or to respond to IL-6. IL-6 is considerably upregulated after immunization with CFA and is detected for several weeks in draining lymph nodes 27 , which suggests that there may be additional factors that support phosphorylated STAT3-mediated signals from IL-23R. As discussed above, it is difficult to investigate the specific requirement of IL-23 for STAT3 because other cytokines, especially IL-6, which is most likely required earlier in T H -17 development, also use STAT3. We therefore designed an in vitro approach to delete STAT3 expression in T H -17 cells at a later point of development. We achieved this by activating CD4 + T cells containing loxP-flanked Stat3 for 4 d with antibody to CD3 (anti-CD3) and anti-CD28 in the presence of TGF-b and IL-6 and then retrovirally expressing Cre recombinase to delete Stat3. With this system, we found that depletion of STAT3 before the second round of stimulation of T H -17 cells in the presence of IL-23 resulted in much less production of IL-17 in those cells (Fig. 3f) . T H -17 cells generated with TGF-b and IL-6 in vitro require the presence of IL-23 during the second round of stimulation with antigen to maintain IL-17 production 12 . Cells without successful deletion of Stat3 (identified as green fluorescent protein-negative (GFP -) cells) still produced IL-17, which indicated that loss of IL-17 production was a direct result of loss of Stat3 in the GFP + cells.
Progression to effector T H -17 cells requires IL-23R
The results thus far suggested that early activation of T H -17 cells may occur normally in the absence of IL-23 and that the defect in function occurs later during the differentiation of effector cells. The expression of several proteins reflects the stage of activation of helper T cells. Corresponding with the normal population expansion of Il23ra -/-cells, early markers of activation seemed unaffected; both wild-type and Il23ra -/-OT-II cells were CD44 hi , CCR7 lo and CD62L lo after immunization of wild-type recipients with OVA (323-339) (Fig. 4a) .
IL-7Ra expression is required for the survival of naive T cells, but IL-7Ra is downregulated after activation of the T cell antigen receptor 28 . Re-expression of IL-7Ra is thought to be important for the survival of effector and memory cells 29, 30 and reflects the progression of differentiation. We found that although IL-7Ra was upregulated on wild-type OT-II cells at day 10 relative to its expression on day 5 after immunization, IL-7Ra was not upregulated in Il23ra -/-OT-II cells (Fig. 4b) . We confirmed that result by quantitative RT-PCR analysis of RNA in cells from the draining lymph nodes of wild-type and Il23ra -/-OT-II mice 7 d after immunization (Fig. 4c) . As the tumor necrosis factor 'superfamily' costimulatory molecule CD27 has been shown to be downregulated in terminally differentiating effector T cells 31 , we also evaluated this cell surface marker. We found that in draining lymph nodes, the percentage of CD27 hi wild-type OT-II cells decreased after day 7 but the percentage of CD27 hi Il23ra -/-OT-II cells did not (Fig. 4d) , which again suggested that the differentiation of effector cells was impaired.
As activated naive cells differentiate toward becoming effector cells, they must leave the lymph node and travel through the circulation to their sites of action in tissues. Evidence of this stems from the fact that wild-type cells of a differentiated phenotype can be found in the blood (for example, most are CD27 lo ) and the fact that many activated effector cells enter the bloodstream as the immune response progresses. On the basis of the less-differentiated phenotype of Il23ra -/-OT-II cells in the lymph nodes, we predicted that there would be fewer OT-II cells in the blood in the absence of IL-23. Indeed, there was a considerable difference in the frequency of activated Il23ra -/-and wild-type OT-II cells in the blood: wild-type OT-II cells began leaving the lymph nodes from day 7, with a peak at day 10; at this time point, an average of 24.35% ± 6.73% (mean ± s.d.) of CD4 + T cells in the blood were OT-II + , compared with only 4.77% ± 0.97% in lymph nodes (absolute numbers correlated with frequencies; data not shown). However, this 'surge' of activated effector cells in the blood did not occur in the absence of IL-23R (Fig. 4e) . Thus, the impaired DTH effector responses we noted earlier (Fig. 3) were the result of not only less production of effector cytokines but also fewer effector cells available to enter tissues. Also, the lower numbers of Il23ra -/-CD4 + cells in the inflamed CNS of the mixed-bone marrow chimeras can thus be attributed to low numbers of effector cells in the blood rather than a failure of those cells to proliferate or survive at that site.
IL-23 promotes a T H -17 effector cytokine profile IL-2 production occurs early after T cell activation and then normally decreases in response to various differentiation factors, correlating with greater production of effector cytokines 32, 33 . IL-2-dependent signaling has also been reported to be required for the re-expression of IL-7Ra in activated T cells 34 and for the suppression of T H -17 induction 35 , both via the transcription factor STAT5. However, IL-2 expression in T H -17 cells developing in vivo has not been well characterized. We found that most wild-type and Il23ra -/-OT-II cells produced IL-2 early after immunization with OVA(323-339) on day 5, and many cells also produced IL-17, whereas few produced only IL-17 ( Fig. 5a-c) .
As the wild-type response progressed, the frequency of single-positive IL-17 + OT-II cells increased (Fig. 5b) , which correlated with a lower frequency of single-positive IL-2 + cells (Fig. 5c) . However, the Il23ra -/-OT-II cells maintained their original phenotype, with the production of few IL-17 + IL-2 -cells (Fig. 5b) and many single-positive IL-2 + cells (Fig. 5c) . Despite the abundant production of IL-2, expression of the high-affinity IL-2 receptor chain CD25 was not maintained on Il23ra -/-OT-II cells (Supplementary Fig. 4 online), which suggested that these cells had limited responsiveness to IL-2. Wild-type OT-II cells consistently had a more differentiated phenotype in the blood than in the lymph node, with greater frequencies of single IL-17 + cells and fewer cells producing IL-2 (Fig. 5d) . However, Il23ra -/-OT-II cell populations in blood included fewer IL-17 + cells than did wild-type OT-II cell populations, which corresponded with the phenotype of the Il23ra -/-cells in the CNS in the mixedbone marrow chimeras (Fig. 2a) .
T H 1 effector cells do not require IL-23R
CFA has long been known to induce T H 1 responses. It was possible that the lower IL-17 production we noted in OT-II cells lacking IL-23R was due to either differentiation of the naive cells to a T H 1 phenotype or conversion of 'undifferentiated' T H -17 cell cells to a T H 1 phenotype. We therefore evaluated the percentage of IL23ra -/-and wild-type OT-II cells that expressed IFN-g alone or both IFN-g and IL-17 after immunization with OVA(323-339). We found similar frequencies of IFN-g + IL-17 -wild-type and Il23ra -/-OT-II cells at all times (Fig. 6a) , which supported our conclusion that T H 1 cells were not induced to 'replace' the loss of the T H -17 phenotype after immunization. In contrast, there was a lower percentage of double-positive IL-17 + IFN-g + IL23ra -/-cells than double-positive IL-17 + IFN-g + wild-type OT-II cells (Fig. 6b) . This result suggested that like IL-17 + T H -17 cells, these cells were dependent on IL-23, whereas IFN-g + IL-17 -cells were dependent on IL-12.
The profound defect in the late activation of the Il23ra -/-OT-II cells suggested that IL-23 could be required for global T cell differentiation. To determine if this was the case, we used a T H 1-dependent infection model to test the function of Il23ra -/-T H 1 effector cells. The production of IFN-g by T cells is absolutely required for host resistance to the parasite Toxoplasma gondii. Thus, a defective T H 1 effector response will cause the host to succumb to this pathogen within 3 weeks of challenge. When we infected wild-type and Il23ra -/-mice with T. gondii and monitored their survival, we found no detectable difference between strains through day 60 of infection ( Fig. 6c) . That result also confirmed published findings showing that IL-23p19 is not required for an effective T H 1 response to this pathogen 36 . When we analyzed the acute response to infection, we found that the frequency of IFN-g + CD4 + cells in the draining lymph nodes was similar among wild-type and Il23ra -/-T cells on day 9 after challenge ( Fig. 6d) and that most of these cells were IL-2 - (Fig. 6e) .
These results again confirmed that T H 1 differentiation is not dependent on IL-23 and that the defects seen were specific to the differentiation of effector T H -17 cells.
IL-23R signaling is required early during differentiation
The results so far suggested that IL-23 was driving the differentiation of effector T H -17 cells, but it was still not clear where in the process of T H -17 differentiation IL-23 signaling was required. To determine that, we used an IL-23R-neutralizing monoclonal antibody to block IL-23 signaling at specific time points after immunization with OVA (323-339) in CFA and measured the outcome on day 10 of the response. A single dose of neutralizing anti-IL-23R at the time of immunization recapitulated the phenotype of Il23ra -/-OT-II cells, as shown by a lower proportion of IL-17 + IL-2 -cells in the draining lymph nodes (Fig. 7a) and lower frequencies of OT-II cells in the blood (Fig. 7b) . Likewise, adding neutralizing antibody specific for IL-23R either 48 h or 96 h after immunization blocked the differentiation of effector T H -17 cells. However, antibody administration at 120 h or later was ineffective, which suggests that days 4-5 are the critical time for receipt of IL-23 signals. These results further support the idea that IL-23 is involved in directing the differentiation of effector T H -17 cells rather than simply maintaining the survival of previously generated effector cells, as the time of action of IL-23 seems to be before most effector cells have developed.
To further confirm that IL-23 signals in CD4 + T cells are required for their differentiation into pathogenic effector cells, we treated SJL mice with a single dose of neutralizing anti-IL-23R at various times after induction of EAE and monitored the mice for clinical signs during primary and relapse phases of disease. Treatment of SJL mice on day 0, 2 or 4 after immunization resulted in complete inhibition of EAE signs up to 6 weeks after immunization (Fig. 7c) , which confirmed the long-lasting inhibition of effector cell differentiation; however, treatment of SJL mice on day 6 after immunization was less effective in inhibiting primary disease. In SJL mice, relapses are triggered by effector T H -17 cells activated during the preceding period of disease 37 . We found that SJL mice treated with anti-IL-23R on day 6 were fully protected from relapsing disease, which showed that although treatment with anti-IL-23R on day 6 did not block a first wave of activated cells, the induction of new effector CD4 + T cells could be prevented.
The timing of the critical function for IL-23 in CD4 + T cells, as demonstrated by the neutralization of IL-23R (described above), suggested that a chief stage of IL-23 signaling in T cells is while they are in the lymph nodes, as this is where most of the activated cells are found on days 4-6. However, IL-23 is thought to be highly expressed in sites of tissue inflammation, and IL-23 was able to enhance effector functions in CNS-derived CD4 + T cells (Fig. 2) . To further confirm that IL-23 can drive the differentiation of effector cells during antigen recognition in the tissues, we tested whether exposure to IL-23 in the skin could restore the impaired DTH response that occurs when T cells have been activated in the absence of IL-23. For this, we transferred wild-type OT-II cells into IL-23p19-deficient (Il23a -/-) recipient mice, which we then challenged to induce DTH at day 10 after immunization. As expected, the response was impaired relative to that of wild-type mice. However, just one administration of recombinant IL-23 at the challenge site resulted in partial restoration of the response (Fig. 7d) ; we used saline plus IL-23 as the contralateral control for OVA plus IL-23, and injection of IL-23 in the absence of antigen did not induce a measurable swelling response in this time frame (data not shown). Given the small numbers of circulating OT-II cells at this time point and the lack of continued IL-23 production, this result is notable. These findings collectively confirm that IL-23 is able to drive effector T H -17 cell function in target organs.
Impaired T H -17 proliferation correlates with failed differentiation
We have thus far shown that IL-23 acts in the lymph nodes to drive the differentiation of effector T H -17 cells, but this does not explain the failure of Il23ra -/-T cells to enter the circulation in large numbers. There are three potential explanations for this: Il23ra -/-T cells are unable to egress from the lymph node; Il23ra -/-IL-17 + T cells die more readily; or Il23ra -/-IL-17 + T cell populations do not expand during the response. In the context of migration, CCR6 has been described as an important chemokine receptor expressed by T H -17 cells 6, 38 . The proportion of wild-type and Il23ra -/-OT-II cells expressing CCR6 at day 10 did not differ much (Fig. 8a) . Sphingosine 1-phosphate (S1P) regulates the egress of lymphocytes from the lymph nodes 39 . Expression of the receptor for S1P (S1P 1 ) was not altered in Il23ra -/-cells relative to that in wild-type OT-II cells on day 7 after immunization ( Fig. 8b) . Although that does not preclude the possibility of different expression of S1P 1 on IL-17 + cells in the total OT-II population, given that finding and the expression of CD62L and CCR7 (Fig. 4a) , it seems unlikely that the failure of large numbers of Il23ra -/-cells to leave the lymph nodes was due to a single defect in the expression of receptors that regulate entry and exit from the lymph nodes. Furthermore, there were not more Il23ra -/-cells than wild-type cells in the lymph nodes, as would be expected if Il23ra -/-cells were accumulating there, which again suggests that failure to migrate was not the main defect. It has been proposed that IL-23 may mediate the survival of T H -17 cells 19 . It is difficult to measure apoptosis in vivo, as dying cells are cleared quickly, but there did not seem to be any difference in the frequency of caspase-3-positive cells with gating on IL-17 -cells (data not shown). There were more caspase-3-positive apoptotic cells in the Il23ra -/-IL-17 + cohort than in the wild-type IL-17 + cohort on day 10 after immunization with OVA (323-339) (Fig. 8c) . That finding correlated with the lower expression of IL-7Ra and lower frequency of IL-17 + cells at this time point, which suggests that as a consequence of IL-23R deficiency, T H -17 cells do become more susceptible to death over time. However, there were already fewer IL-17 + cells by day 7 and very few by day 10, so it seems unlikely that this effect is sufficient to explain the difference in frequencies of cells in the blood at day 10.
In terms of the survival and maintenance of cells of the T H -17 phenotype, IL-21 is known to act as an autocrine growth factor for T H -17 development and is induced by IL-6 and IL-23 and by IL-21 itself 18, 40, 41 . To assess whether IL-21 induction was affected by IL-23R deficiency, we purified OT-II T cells from draining lymph nodes on day 7 after immunization. Expression of IL-21 mRNA was equally higher in both wild-type and Il23ra -/-OT-II T cells than in control nontransgenic (OT-II -) CD4 + cells isolated from the same lymph node (Fig. 8d) . Therefore, it seems that IL-23 is not required for IL-21 production and most likely that IL-6 and IL-21 itself are sufficient.
Our final hypothesis was that the proliferation of activated IL-17 + Il23ra -/-T cells was lower, which resulted in fewer effector cells. We therefore assessed the proportion of OT-II cells in cycle at various time points by measuring incorporation of the thymidine analog BrdU at 4 h after its administration in vivo. By focusing in on IL-17 production, we found that IL-23R deficiency resulted in significantly fewer proliferating IL-17 + cells on day 7 (Fig. 8e) . In contrast, the frequency of Il23ra -/-IL-17 -cells was similar to that of wild-type cells at earlier time points but frequency of cells in cycle was significantly lower on day 10 (Fig. 8f) , at which point the Il23ra -/-population also had lower IL-17 production (Fig. 3c) . Although single-positive IL-17 + cells had incorporated the most BrdU, the difference in the proliferation of wild-type and Il23ra -/-IL-17 + cells could not be further distinguished on the basis of IL-2 expression in the IL-17 + cells (data not shown). The finding that IL-17 + cells proliferated less on day 7 is important, because this time point provides the link between the requirement for IL-23 on day 5 and the large defects that become most apparent on day 10 (lower IL-17 production and a lack of effector cells in the blood). We also confirmed lower cycling in the absence of IL-23 in the draining lymph nodes and CNS of mixed-bone marrow chimeric mice at 11 d after immunization to induce EAE (Supplementary 32 and, as already discussed, activated T cells in the blood have a more differentiated phenotype than do those in the lymph nodes. These results collectively support the conclusion that IL-23 drives the expansion of developing T H -17 effector cell populations.
DISCUSSION
In this study we have compared the function of IL-23R in the EAE, OT-II and DTH models and found concordance in our results. During the initial 5-7 d of the response, OT-II cells were unaffected by IL-23R deficiency and their frequencies in the blood were similar to those of wild-type cells. Likewise, at an early time point in the chimera EAE system, the ratio of wild-type to Il23ra -/-CD4 + cells in the CNS was unaffected, although cell numbers were very low. At day 10, there were obvious functional defects apparent in the phenotype of the Il23ra -/-OT-II cells, and their frequency in the blood remained low in contrast to the large increase in wild-type cells. Similarly, at the onset of EAE (day 11), it was apparent that the number of Il23ra -/-CD4 + cells had not greatly increased in the CNS compared with wild-type cells, and the Il23ra -/-CD4 + cells that were present were not producing IL-17, consistent with the low frequency of Il23ra -/-antigen-specific effector cells available to enter the CNS from the circulation at this time point. Therefore, we can combine results from these two systems to elucidate the requirements for IL-23 signaling during T H -17 development in lymph nodes and T H -17 effector function in target tissues.
Our results have identified a far more central function for IL-23 in T H -17 differentiation than previously thought. As expected, early T H -17 development seemed normal in the absence of IL-23R, with population expansion of antigen-specific T cells and induction of IL-17. However, these cells did not progress in their differentiation and did not downregulate CD27 or re-upregulate IL-7Ra. Il23ra -/-cells also failed to generate large numbers of IL-17-producing progeny that could enter the bloodstream and therefore did not infiltrate tissues in large numbers or successfully initiate inflammation. The number of activated T cells in the lymph node at any given time is a function of the rates of proliferation, death and migration. The results presented here suggest that the lower proliferation rate of Il23ra -/-OT-II cells, particularly IL-17 + cells, later in the response results in the failure to generate large numbers of cells that egress into the blood and that together these two factors balance so that the overall number of OT-II cells in the lymph nodes is not greatly altered relative to that of wild-type cells. Given that the Il23ra -/-population never attained a high frequency of single IL-17 + or CD27 lo cells and that there was not a great increase in apoptotic cells, it seems likely that the actual generation of effector cells, rather than the survival of these effector cells, is affected. This would be consistent with the lower BrdU uptake and proliferation rate in the absence of IL-23, as cell division is known to be linked with cellular differentiation 32 . We therefore conclude that the main function of IL-23 in T H -17 biology is to drive terminal differentiation; in its absence, T H -17 cells experience 'arrested development' , which leads to impaired function.
The following question then arises: is IL-23 merely driving the proliferation of developing T H -17 cells and thus facilitating their differentiation? Several observations suggest that this is not the case. In the initial description of the main function of IL-23 rather than IL-12 in EAE induction, forced expression of IL-23 in the brain of IL-23-deficient mice was able to restore their susceptibility to inflammation 2 . With the OT-II model, we have shown here that injection of IL-23 in the site of antigen challenge was able to partially restore the DTH response in IL-23-deficient mice. These two findings suggest that although the generation of T H -17 effector cells in the lymph nodes is greatly impaired in the absence of IL-23, for the few cells that do migrate into the blood, exposure to IL-23 in the periphery may be sufficient to activate effector function (drive terminal differentiation) to an amount sufficient to induce inflammation. In the DTH model, we used one injection of soluble cytokine and found that the response was temporary. In the EAE experiments, adenoviral expression resulted in more sustained IL-23 production, which most likely explains the greater efficacy in disease induction. In addition, IL-23 enhanced IL-17 production by CNS-derived T cells in a short time period in vitro, and IL-23 has been shown to be required for the production of other T H -17-associated proinflammatory cytokines, such as IL- 22 (refs. 15,16) . Such studies collectively support the hypothesis that IL-23 can act both in the lymph nodes and peripheral tissues to drive the terminal differentiation of effector cells and that the proliferation of cells developing in lymph nodes is only one facet of the functions of IL-23 in promoting T H -17-mediated inflammation.
The failure of IL-23R-deficient T cells to re-express IL-7Ra after activation may have long-term consequences for these cells. Although it is downregulated during early activation, re-expression of IL-7Ra is required for the survival of effector and memory T cells 29, 30, 34 . Few data are available on whether effective T H -17 memory responses can be generated in autoimmune models, but two vaccination studies with the pathogens Mycobacterium tuberculosis and Bordetella pertussis suggest this is possible 43, 44 . Greater numbers of apoptotic CD4 + T cells have been reported after long-term in vivo neutralization of IL-23 in a colitis model, although the mechanisms for this are not clear 19 . Indeed, we also noted slightly more caspase-3-positive IL-17 + Il23ra -/-cells on day 10, although the low frequency of IL-17 + cells makes it difficult to assess the importance of this observation. Overall, then, it seems likely that the survival of effector T H -17 cells and/or formation of memory T H -17 cells would be impaired in the absence of signals from IL-23.
T H -17 development is known to depend on STAT3 signaling 17,24,25 and expression of the transcriptional regulators RORgt 10 and RORa 45 . It has also been suggested that STAT4 may contribute to T H -17 development, as cells from 'STAT4-knockout' mice have partially lower IL-17 production 25 , although other studies have reported no STAT4 involvement 46, 47 , and we were unable to detect large amounts of STAT4 phosphorylation in T cells after stimulation with IL-23 (data not shown). IL-6, IL-21 and IL-23 are all strong activators of STAT3 phosphorylation, and as IL-6 and possibly IL-21 are required for the early differentiation of T H -17 cells, it is very difficult to investigate the requirement for STAT3 phosphorylation by IL-23 during later differentiation. However, we were able to confirm that STAT3 was phosphorylated by IL-23 ex vivo in developing T H -17 cells, and also that STAT3 was required for the production of IL-17 by T H -17 cells in vitro.
Hence, we believe that IL-23 acts through STAT3, although there may also be additional pathways activated.
In conclusion, we have shown here that IL-23R was required for the terminal differentiation and therefore the function of T H -17 cells in vivo. Our findings also have important implications for targeting IL-23 and its receptor therapeutically in T H -17-mediated diseases in humans. Our results suggest that the beneficial effects of neutralizing IL-23 may not be instantaneous, as IL-23 promotes but does not seem to be required for the effector functions of already generated T H -17 cells. However, the effects should be long lasting, as the ongoing generation of T H -17 cells should be blocked and potentially T H -17 memory responses will be impaired, thereby affecting the rate of disease relapse, as we have noted in the EAE model. In addition, the 'upstream' position of IL-23 in inflammatory cascade relative to 'downstream' mediators such as tumor necrosis factor allows hope for greater efficacy. In some diseases, such as psoriasis, there are indications that IL-23 acts not only on T H -17 cells but also on innate immune cells, and in such circumstances, targeting IL-23 may prove even more effective. The success of anti-IL-12p40 in treating psoriasis in clinical trials 48 suggests that this may be the case, but clinical testing of IL-23 neutralization will specifically address this question.
METHODS
Mice. The generation of Il23ra -/-mice has been described 21 . Mixed-bone marrow chimeras were generated as described ( Supplementary Fig. 1 ). Il23ra -/-OT-II CD45.1 + mice were generated at Schering Plough Biopharma. All animal procedures were approved by the Institutional Animal Care and Use Committee of Schering Plough Biopharma in accordance with guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care.
Reagents. The following flow cytometry antibodies were from BD Biosciences: anti-CD4 (RM4-5), anti-CD45.1 (A20), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD27 (LG.3A10), anti-CD25 (7D4), anti-CCR6 (140706), anti-BrdU (antibody to 5-bromodeoxyuridine; 51-23619L; used with the BrdU staining kit from BD according to the manufacturer's instructions), anti-IFN-g (XMG1.2), anti-IL-17 (TC11-18H10), anti-IL-2 (JES6-5H4I; used for intracellular cytokine staining with the Cytofix/Cytoperm kit from BD according to the manufacturer's instructions), antibody to STAT3 phosphorylated at Tyr705 (4-P-STAT3; used with the Phosflow staining kit from BD according to the manufacturer's instructions) and antibody to the active form of caspase-3 (C92-605). The following antibodies were from eBioscience: anti-CCR7 (4B12), anti-Foxp3 (FJK-16s; used with the Foxp3 staining kit from eBioscience according to the manufacturer's instructions) and anti-IL-7Ra (A7R34).
EAE. C57BL/6 mice (including Il23ra -/-and mixed-bone marrow chimeras) were immunized in four sites on the back with 100 mg MOG(35-55) in 200 ml CFA containing 100 mg M. tuberculosis strain H37Ra. SJL mice were immunized in four sites on the back with 100 mg of a peptide of proteolipid protein, amino acids 139-151, in 200 ml CFA containing 20 mg heat-killed M. tuberculosis strain H37Ra (Difco). All mice also received 100 ng pertussis toxin (List Biological Laboratories) intraperitoneally on days 0 and 2. Mice were assigned clinical scores for EAE according to the following scale: 1, flaccid tail; 2, impaired righting reflex and hindlimb weakness; 3, partial hindlimb paralysis; 4, complete hindlimb paralysis; 5, hindlimb paralysis with partial forelimb paralysis; 6, moribund.
OT-II tracking studies. Recipient mice (CD45.2 + ) received 1 Â 10 5 CD45.1 + Il23ra -/-or Il23ra +/+ OT-II CD4 + T cells or a 50/50 mixture of Il23ra -/-and Il23ra +/+ OT-II CD4 + T cells intravenously 1 d before being immunized subcutaneously in the flank with 100 mg OVA(323-339) in CFA. The phenotype of OT-II + cells was assessed by flow cytometry with gating on live CD4 + CD45.1 + cells, except for caspase-3 analysis, for which all lymphocytes were included in the analysis. For BrdU analysis, mice were injected intraperitoneally with 1 mg BrdU (BD Biosciences) 4 h before being killed. Intracellular phosphorylated STAT3 was measured with a BD Phosflow protocol as directed by the manufacturer.
T cell stimulation for cytokine analysis. CNS mononuclear cells were isolated as described 2,4 from mixed-bone marrow chimeras with EAE and cells were cultured for 24 h in complete medium (RPMI medium containing 10% (vol/vol) FCS, supplemented with penicillin and streptomycin, L-glutamine, HEPES, pH 7.2, sodium pyruvate and 2-mercaptoethanol) with MOG(35-55) (100 mg/ml) in the presence or absence of IL-23 (SPB). GolgiPlug (BD Biosciences) was added for the final 4 h of culture before flow cytometry. For stimulation of OT-II T cells ex vivo for cytokine analysis, draining lymph nodes were collected at various time points after immunization and single-cell suspensions were obtained. Cells were stimulated for 4 h with phorbol 12-myristate 13-acetate (50 ng/ml) and ionomycin (500 ng/ml; both from Sigma-Aldrich) in the presence of GolgiPlug (BD Biosciences) in complete medium, followed by flow cytometry staining and analysis. For stimulation of OT-II cells ex vivo for analysis of STAT3 phosphorylation, suspensions of cells from draining lymph nodes were incubated for 15 min with complete medium alone, IL-23 (50 ng/ml) or IL-6 (50 ng/ml).
DTH. Wild-type recipients of wild-type or Il23ra -/-OT-II cells were immunized with OVA (323-339) and then challenged in one hind footpad with 100 mg OVA in saline; the contralateral footpad was injected with saline. Foot thickness was measured with calipers (Mitutoyo), and results are presented as thickness relative to the thickness produced by the saline control. Where indicated, 7 mg IL-23 was given in addition to OVA or the saline control.
T. gondii infection. Age-matched female C57BL/6 or knockout mice were infected intraperitoneally with 20 cysts of T. gondii strain ME-49. Draining lymph nodes were removed from mice at day 9 after infection and were cultured for 4 h with GolgiStop in the presence or absence of phorbol 12-myristate 13-acetate and ionomycin. Cells were then stained with Pacific blue-conjugated anti-CD4, phycoerythrin-conjugated anti-IL-2 and allophycocyanin-conjugated anti-IFN-g before analysis by flow cytometry for the presence of cytokineproducing T cells.
Retroviral depletion of STAT3. Naive (CD62L + CD44 -) CD4 + cells containing loxP-flanked Stat3 were stimulated for 3 d with anti-CD3 and anti-CD28 in the presence of TGF-b (5 ng/ml), IL-6 (10 ng/ml) and anti IL-2 (10 mg/ml). Cells were washed on day 3 and were allowed to expand their populations for 4 d in the presence of IL-2. During this time, cells were infected with the retrovirus MIGR-GFP (control) or Cre-GFP in the presence of polybrene (4 mg/ml). On day 8, cells were restimulated for an additional 3 d in the presence or absence of IL-23 (10 ng/ml).
IL-23R neutralization in vivo.
Mouse monoclonal antibody to mouse IL-23R (21A4) was generated at Schering-Plough Biopharma. A single dose of 200 mg was delivered intraperitoneally on various days after immunization with OVA(323-339) or after the induction of EAE with proteolipid protein, amino acids 139-151.
Statistics: Where appropriate, a one-way analysis of variance (for multiple groups) or Student's t-test was done. P values are presented where statistical significance was found.
Note: Supplementary information is available on the Nature Immunology website.
